Related Experiment Video

Updated: Aug 7, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate

Jonathan E Dowell1

  • 1Departments of Internal Medicine, University of Texas Southwestern Medical Center, and the Dallas Veterans Affairs Medical Center, Dallas, Texas 75390-8852, USA. jonathan.dowell@utsouthwesten.edu

The American Journal of the Medical Sciences
|March 16, 2006
PubMed

Insights

Targeting the epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors (TKI) shows promise for non-small cell lung cancer (NSCLC). Specific EGFR mutations predict patient response to these targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Preclinical studies indicated the epidermal growth factor receptor (EGFR) as a viable therapeutic target for non-small cell lung cancer (NSCLC).
  • This led to the development of selective EGFR tyrosine kinase inhibitors (TKIs), which offer symptomatic relief and improved survival in advanced NSCLC patients.

Purpose of the Study:

  • To identify molecular predictors of response to EGFR tyrosine kinase inhibitor (TKI) therapy in non-small cell lung cancer (NSCLC).
  • To explore the implications of these predictors for future cancer drug development.

Main Methods:

  • Review of preclinical data and clinical outcomes for EGFR-targeted therapies.
  • Analysis of recent findings on somatic mutations in EGFR and their correlation with TKI response.

Main Results:

  • The identification of specific somatic mutations within the EGFR gene predicts patient response to EGFR tyrosine kinase inhibitors.
  • These mutations serve as crucial biomarkers for treatment selection in NSCLC.

Conclusions:

  • Somatic EGFR mutations are key determinants of response to EGFR TKIs in NSCLC.
  • This discovery has significant implications for personalized medicine in lung cancer and broader applications in developing targeted therapies for other malignancies.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity: